Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Long Term Safety Trial to Compare Insulin Treatment With Preprandial Inhaled Human Insulin to s.c. Insulin Aspart Both Combined With NPH in Subjects With Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 305
- Registration Number
- NCT00725036
- Locations
- 🇦🇺
Novo Nordisk Investigational Site, Stones Corner, Australia
Dose Study in Healthy Japanese Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083
- First Posted Date
- 2008-07-25
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 40
- Registration Number
- NCT00722540
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Observational Study to Evaluate Safety and Efficacy of Insulin Therapy in Type 2 Diabetes Mellitus Subjects Failing on Oral Anti-diabetic Agents
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: soluble human insulinDrug: biphasic human insulin
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1667
- Registration Number
- NCT00715780
- Locations
- 🇮🇩
Novo Nordisk Investigational Site, Jakarta, Indonesia
Observational Study of Patients Using Levemir® or Insulatard® as Start Insulin for Treatment of Diabetes
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2016-11-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 342
- Registration Number
- NCT00715351
- Locations
- 🇸🇮
Novo Nordisk Investigational Site, Ljubljana, Slovenia
Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 Diabetes
Completed
- Conditions
- Diabetes Mellitus, Type 2Delivery SystemsDiabetes
- Interventions
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1584
- Registration Number
- NCT00715663
- Locations
- 🇮🇩
Novo Nordisk Investigational Site, Jakarta, Indonesia
Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083
Phase 2
Completed
- Conditions
- Growth Hormone DisorderAdult Growth Hormone Deficiency
- Interventions
- Drug: placebo
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 33
- Registration Number
- NCT00715689
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Århus C, Denmark
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
Phase 3
Completed
- Conditions
- Congenital Bleeding DisorderCongenital FXIII Deficiency
- Interventions
- First Posted Date
- 2008-07-11
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 41
- Registration Number
- NCT00713648
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Newcastle upon Tyne, United Kingdom
Observational Study Describing Conditions for Intensification of Insulin Therapy in Type 2 Diabetes
- First Posted Date
- 2008-07-10
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 114
- Registration Number
- NCT00712478
Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia B With InhibitorsHaemophilia A With Inhibitors
- Interventions
- Drug: activated recombinant human factor VII
- First Posted Date
- 2008-07-04
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 52
- Registration Number
- NCT00710619
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Plainsboro, New Jersey, United States
Observational Study to Evaluate the Safety of NovoMix® 30 FlexPen®
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 216
- Registration Number
- NCT00709683
© Copyright 2025. All Rights Reserved by MedPath